Aquaporin 3 inhibition suppresses the mitochondrial respiration rate and viability of multiple myeloma cells.

Aquaporin 3 (AQP3) is a member of the aquaporin water channel family expressed by numerous cell types, including some cancer cells. Accumulating evidence suggests that AQP3 inhibition may impede cancer progression, but drugs targeting AQP3 are still in the early pre-clinical stage of development. Here, we examined the effect of AQP3 inhibition on multiple myeloma (MM), an incurable plasma cell malignancy. Four MM cell lines were cultured in the presence of an anti-AQP3 monoclonal antibody (mAb), the AQP3 inhibitor DFP00173, or corresponding controls, and the effects on cell viability, proliferation, apoptosis, and mitochondrial respiration capacity were compared. Both anti-AQP3 mAb and DFP00173 reduced cell growth, mitochondrial respiration rate, and electron transport chain complex I activity. Both agents also potentiated the antiproliferative efficacy of the anticancer drug venetoclax. Administration of the anti-AQP3 mAb to immunodeficient mice inoculated with RPMI8226 or KMS-11 MM cells significantly suppressed tumor growth. These data provide evidence that AQP3 blockade can suppress MM cell growth in vitro and tumor growth in mice. Thus, AQP3 inhibition may be an effective therapeutic strategy for MM. • AQP3 blockade with anti-AQP3 mAb or AQP3 inhibitor reduced multiple myeloma (MM) cell viability and growth. • AQP3 blockade suppressed the mitochondrial respiration rate and ETC complex 1 activity in MM cells. • Administration of anti-AQP3 mAb attenuated MM xenograft tumor development in mice. • AQP3 inhibition is a potential therapeutic strategy for MM. [ABSTRACT FROM AUTHOR]